Skip to main content
PMC home page
Thorax logoLink to Thorax
. 1998 Apr;53(4):265–268. doi: 10.1136/thx.53.4.265

Clinical features and prognosis of life time non-smokers with severe α1-antitrypsin deficiency

N Seersholm 1, A Kok-Jensen 1
PMCID: PMC1745189  PMID: 9741368

Abstract

BACKGROUND—The hereditary disorder α1-antitrypsin deficiency is characterised by development of severe emphysema at an early age with smoking being the most significant additional risk factor. The purpose of the present paper was to analyse potential risk factors other than smoking for emphysema and to estimate the prognosis of life time non-smokers.
METHODS—Patients were identified through the files of the Danish α1-antitrypsin deficiency register which contains information on more than 700 persons with the condition. Many of the patients, the non-index cases, were identified from family studies.
RESULTS—There were 75 life time non-smokers with PiZ (27 index cases and 48 non-index cases) aged 20 years or more at entry. Twenty one subjects died during the follow up period. The Standardised Mortality Ratio (SMR) was 3.0 (95% confidence intervals (CI) 1.9to 4.6). There was no significant difference in SMR between males and females. The SMR was 8.8 (95% CI 5.0 to 14) for the index cases and 0.96 (95% CI 0.3 to 2.3) for the non-index cases based on five deaths. The overall mean % predicted forced expiratory volume in one second (FEV1) at entry was 83% with a significant difference between index cases (54%) and non-index cases (100%) (p<0.001). The difference in the ratio of FEV1 to forced vital capacity (FVC) was also highly significant with values of 0.57and 0.79 for index and non-index cases, respectively (p<0.001). In the non-index group only three had an FEV1% predicted of less than 70%.
CONCLUSIONS—Occupational exposure to airway irritants did not have any significant influence on the development of emphysema. Only a few life time non-smokers develop severe emphysema; most never develop pulmonary symptoms and thus remain undetected unless family members of index cases are screened.



Full Text

The Full Text of this article is available as a PDF (128.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Black L. F., Kueppers F. alpha1-Antitrypsin deficiency in nonsmokers. Am Rev Respir Dis. 1978 Mar;117(3):421–428. doi: 10.1164/arrd.1978.117.3.421. [DOI] [PubMed] [Google Scholar]
  2. Brantly M. L., Paul L. D., Miller B. H., Falk R. T., Wu M., Crystal R. G. Clinical features and history of the destructive lung disease associated with alpha-1-antitrypsin deficiency of adults with pulmonary symptoms. Am Rev Respir Dis. 1988 Aug;138(2):327–336. doi: 10.1164/ajrccm/138.2.327. [DOI] [PubMed] [Google Scholar]
  3. Brantly M., Nukiwa T., Crystal R. G. Molecular basis of alpha-1-antitrypsin deficiency. Am J Med. 1988 Jun 24;84(6A):13–31. doi: 10.1016/0002-9343(88)90154-4. [DOI] [PubMed] [Google Scholar]
  4. Burrows B., Knudson R. J., Lebowitz M. D. The relationship of childhood respiratory illness to adult obstructive airway disease. Am Rev Respir Dis. 1977 May;115(5):751–760. doi: 10.1164/arrd.1977.115.5.751. [DOI] [PubMed] [Google Scholar]
  5. Donner C. F., Howard P., Robert D. Patient selection and techniques for home mechanical ventilation. Eur Respir J. 1993 Jan;6(1):3–4. [PubMed] [Google Scholar]
  6. Eriksson S. Studies in alpha 1-antitrypsin deficiency. Acta Med Scand Suppl. 1965;432:1–85. [PubMed] [Google Scholar]
  7. Fagerhol M. K., Cox D. W. The Pi polymorphism: genetic, biochemical, and clinical aspects of human alpha 1-antitrypsin. Adv Hum Genet. 1981;11:1-62, 371-2. [PubMed] [Google Scholar]
  8. Janus E. D., Phillips N. T., Carrell R. W. Smoking, lung function, and alpha 1-antitrypsin deficiency. Lancet. 1985 Jan 19;1(8421):152–154. doi: 10.1016/s0140-6736(85)91916-6. [DOI] [PubMed] [Google Scholar]
  9. Larsson C. Natural history and life expectancy in severe alpha1-antitrypsin deficiency, Pi Z. Acta Med Scand. 1978;204(5):345–351. doi: 10.1111/j.0954-6820.1978.tb08452.x. [DOI] [PubMed] [Google Scholar]
  10. McNeil T. F., Sveger T., Thelin T. Psychosocial effects of screening for somatic risk: the Swedish alpha 1 antitrypsin experience. Thorax. 1988 Jul;43(7):505–507. doi: 10.1136/thx.43.7.505. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Piitulainen E., Tornling G., Eriksson S. Effect of age and occupational exposure to airway irritants on lung function in non-smoking individuals with alpha 1-antitrypsin deficiency (PiZZ). Thorax. 1997 Mar;52(3):244–248. doi: 10.1136/thx.52.3.244. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Poller W., Faber J. P., Olek K. Highly variable clinical course in severe alpha 1-antitrypsin deficiency--use of polymerase chain reaction for the detection of rare deficiency alleles. Klin Wochenschr. 1990 Sep 3;68(17):857–863. doi: 10.1007/BF01662782. [DOI] [PubMed] [Google Scholar]
  13. Seersholm N., Kok-Jensen A., Dirksen A. Decline in FEV1 among patients with severe hereditary alpha 1-antitrypsin deficiency type PiZ. Am J Respir Crit Care Med. 1995 Dec;152(6 Pt 1):1922–1925. doi: 10.1164/ajrccm.152.6.8520756. [DOI] [PubMed] [Google Scholar]
  14. Seersholm N., Kok-Jensen A., Dirksen A. Survival of patients with severe alpha 1-antitrypsin deficiency with special reference to non-index cases. Thorax. 1994 Jul;49(7):695–698. doi: 10.1136/thx.49.7.695. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Silverman E. K., Pierce J. A., Province M. A., Rao D. C., Campbell E. J. Variability of pulmonary function in alpha-1-antitrypsin deficiency: clinical correlates. Ann Intern Med. 1989 Dec 15;111(12):982–991. doi: 10.7326/0003-4819-111-12-982. [DOI] [PubMed] [Google Scholar]
  16. Silverman E. K., Province M. A., Campbell E. J., Pierce J. A., Rao D. C. Biochemical intermediates in alpha 1-antitrypsin deficiency: residual family resemblance for total alpha 1-antitrypsin, oxidized alpha 1-antitrypsin, and immunoglobulin E after adjustment for the effect of the Pi locus. Genet Epidemiol. 1990;7(2):137–149. doi: 10.1002/gepi.1370070204. [DOI] [PubMed] [Google Scholar]
  17. Silverman E. K., Province M. A., Campbell E. J., Pierce J. A., Rao D. C. Family study of alpha 1-antitrypsin deficiency: effects of cigarette smoking, measured genotype, and their interaction on pulmonary function and biochemical traits. Genet Epidemiol. 1992;9(5):317–331. doi: 10.1002/gepi.1370090504. [DOI] [PubMed] [Google Scholar]
  18. Stoller J. K., Smith P., Yang P., Spray J. Physical and social impact of alpha 1-antitrypsin deficiency: results of a survey. Cleve Clin J Med. 1994 Nov-Dec;61(6):461–467. doi: 10.3949/ccjm.61.6.461. [DOI] [PubMed] [Google Scholar]
  19. Sveger T., Piitulainen E., Arborelius M., Jr Clinical features and lung function in 18-year-old adolescents with alpha 1-antitrypsin deficiency. Acta Paediatr. 1995 Jul;84(7):815–816. doi: 10.1111/j.1651-2227.1995.tb13765.x. [DOI] [PubMed] [Google Scholar]
  20. Sveger T., Thelin T., McNeil T. F. Young adults with alpha 1-antitrypsin deficiency identified neonatally: their health, knowledge about and adaptation to the high-risk condition. Acta Paediatr. 1997 Jan;86(1):37–40. doi: 10.1111/j.1651-2227.1997.tb08828.x. [DOI] [PubMed] [Google Scholar]
  21. Tobin M. J., Cook P. J., Hutchison D. C. Alpha 1 antitrypsin deficiency: the clinical and physiological features of pulmonary emphysema in subjects homozygous for Pi type Z. A survey by the British Thoracic Association. Br J Dis Chest. 1983 Jan;77(1):14–27. doi: 10.1016/0007-0971(83)90002-5. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES